MAZE
Maze Therapeutics, Inc. Common StockMAZE
MAZE
–
Funds holding %
of 7,398 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$19
93%
upside
Avg. target
$26
161%
upside
High target
$30
205%
upside
3 analyst ratings
3 positive
100%
0 neutral
0%
0 negative
0%
Guggenheim Debjit Chattopadhyay 32% 1-year accuracy 7 / 22 met price target | 93%upside $19 | Buy Initiated | 25 Feb 2025 |
Leerink Partners Joseph Schwartz 43% 1-year accuracy 3 / 7 met price target | 184%upside $28 | Outperform Initiated | 25 Feb 2025 |
JP Morgan Anupam Rama 24% 1-year accuracy 15 / 62 met price target | 205%upside $30 | Overweight Initiated | 25 Feb 2025 |
Financial journalist opinion
Neutral
GlobeNewsWire
1 day ago
Maze Therapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Highlights
MZE829 Phase 2 HORIZON Trial Enrolling Patients with APOL1 Kidney Disease (AKD); Initial Data Expected in Q1 2026 MZE782 Phase 1 Healthy Volunteer Trial Ongoing; Initial Data Expected in H2 2025 Raised $140 Million in Gross Proceeds in Upsized IPO in February 2025, Providing Expected Cash Runway into H2 2027 SOUTH SAN FRANCISCO, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with renal, cardiovascular and metabolic diseases, today reported financial results for the fourth quarter and year ended December 31, 2024, highlighted recent progress and reiterated upcoming milestones.
Neutral
GlobeNewsWire
1 month ago
Maze Therapeutics Doses First Patient in Phase 2 HORIZON Clinical Trial Evaluating MZE829 as a Potential Treatment for APOL1 Kidney Disease
SOUTH SAN FRANCISCO, Calif., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular, and metabolic diseases, today announced the first patient has been dosed in the company's Phase 2 clinical trial, the HORIZON Study, of MZE829 in patients with APOL1 kidney disease (AKD).
Positive
Seeking Alpha
1 month ago
U.S. IPO Weekly Recap: Active January Closes Out With Several Sizable IPOs
Five IPOs listed this week, all of which raised over $100 million; one direct listing and three SPACs also debuted. Four microcaps submitted initial filings this week - Vistek, Awaysis Capital, QMSK Technology, and TV Channels Network. Two IPOs are currently scheduled for the week ahead, and a few more sizable names are eligible to launch.
Neutral
Reuters
1 month ago
Maze Therapeutics valued at $690.4 million as shares rise marginally in market debut
Shares of Maze Therapeutics rose nearly 1% in their Nasdaq debut on Friday, valuing the kidney disease drug developer at $690.37 million.
Positive
Reuters
1 month ago
Biotech firm Maze Therapeutics raises $140 million in US IPO
Maze Therapeutics said on Thursday that it raised $140 million in an initial public offering, setting the stage for a debut that could make the kidney disease drug developer the first U.S. biotech listing this year.
Neutral
GlobeNewsWire
1 month ago
Maze Therapeutics Announces Pricing of Upsized Initial Public Offering
SOUTH SAN FRANCISCO, Calif., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, today announced the pricing of its upsized initial public offering of 8,750,000 shares of its common stock at a public offering price of $16.00 per share. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses, are expected to be $140.0 million. All shares of common stock to be sold in the offering will be sold by Maze Therapeutics. In addition, Maze Therapeutics has granted the underwriters a 30-day option to purchase up to an additional 1,312,500 shares of common stock at the initial public offering price, less underwriting discounts and commissions. The shares are expected to begin trading on the Nasdaq Global Market on January 31, 2025, under the symbol “MAZE.” The offering is expected to close on February 3, 2025, subject to the satisfaction of customary closing conditions.
Positive
Reuters
2 months ago
Maze Therapeutics targets up to $728 mln valuation in US IPO
Drug developer Maze Therapeutics said on Monday it was targeting a valuation of as much as $728.1 million in its initial public offering in the United States.
Positive
Seeking Alpha
2 months ago
Maze Therapeutics Seeks IPO For Trials Ramp-Up
Maze Therapeutics aims to raise $100 million in an IPO to fund clinical trials for its kidney and related disease treatments. The company's lead candidate, MZE829, is in Phase 2 trials for APOL1 kidney disease, with promising Phase 1 results. Maze has strong financial backing and a significant partnership with Shionogi & Co., positioning it well for future development.
Charts implemented using Lightweight Charts™